Last reviewed · How we verify
biologic DMARDs
Biologic DMARDs are immunosuppressive agents that target specific immune pathways to reduce inflammation and slow disease progression in autoimmune conditions.
Biologic DMARDs are immunosuppressive agents that target specific immune pathways to reduce inflammation and slow disease progression in autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions (specific agents vary).
At a glance
| Generic name | biologic DMARDs |
|---|---|
| Also known as | rimicade, adalimumab |
| Sponsor | Kasr El Aini Hospital |
| Drug class | Biologic DMARD (disease-modifying antirheumatic drug) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Biologic disease-modifying antirheumatic drugs (DMARDs) work by targeting key components of the immune system, such as TNF-alpha, IL-6, T-cell co-stimulation, or B-cells, to suppress the inflammatory cascade driving autoimmune disease. By blocking these specific molecular targets, they reduce joint inflammation, prevent tissue damage, and improve clinical outcomes in conditions like rheumatoid arthritis. This class includes TNF inhibitors, IL-6 inhibitors, T-cell co-stimulators, and B-cell depleting agents.
Approved indications
- Rheumatoid arthritis
- Other autoimmune inflammatory conditions (specific agents vary)
Common side effects
- Infection (including serious infections)
- Injection site reactions
- Infusion reactions
- Malignancy risk
- Tuberculosis reactivation
Key clinical trials
- The SetPoint System Safety & Performance Post-Approval Study
- Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (PHASE3)
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (PHASE3)
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Modifying PEST for Psoriatic Arthritis Screening (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biologic DMARDs CI brief — competitive landscape report
- biologic DMARDs updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI